- GenapSys, a company developing a highly accurate and scalable electronic sequencing platform, announced it has raised $70 million in a Series D round.
GenapSys — a company developing a highly accurate and scalable electronic sequencing platform — announced it has raised $70 million in a Series D equity financing. And the investors in the round included Farallon Capital Management, L.L.C., Soleus Capital, an affiliate of PBM Capital, and additional new investors. The proceeds from this financing will be used to continue advancing GenapSys’ semiconductor based next-generation sequencing (NGS) platform.
Plus Bob Zollars and a representative of Farallon Capital have been appointed to GenapSys’ Board of Directors.
Zollars is a senior advisor at Frazier Healthcare Partners in their growth equity business. And previously, Zollars was group president at Cardinal Health and was responsible for 5 of their subsidiary companies, he also led 4 different operating divisions at Baxter Healthcare. Plus he was chairman and CEO of Vocera Communications and was previously chairman and CEO of Neoforma, where he led both companies through successful IPO’s.
KEY QUOTES:
“We are delighted to partner with this world-class group of investors who together share our broad strategic vision of delivering an affordable, scalable genomic sequencing ecosystem that empowers both academic and clinical research. We look forward to leveraging our Board’s strategic insight to accelerate new product development, particularly within the oncology arena.”
— Jason Myers, Ph.D., Chief Executive Officer of GenapSys
“This latest round of funding is a testament to the strength and momentum of GenapSys’ technology. The world is just beginning to unlock the immense potential of genomic sequencing and this capital will help fuel GenapSys’ next stage of growth. We’re honored to welcome these world-class investors and expand the GenapSys Board of Directors.”
— GenapSys Founder and Chairman Dr. Hesaam Esfandyarpour
“GenapSys’ development of an affordable and highly scalable genomic sequencing ecosystem has the potential to transform the human condition. With the Company’s sequencing technology, researchers and clinicians that previously lacked access to sequencing options will be enabled to better understand and treat disease. I am excited to serve as the Company’s lead independent director.”
— Bob Zollars
